SR33805|cas:121345-64-0|西域试剂

SR33805,99.19%

产品编号：Bellancom-136909| CAS NO：121345-64-0| 分子式：C₃₂H₄₀N₂O₅S| 分子量：564.74

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-136909	￥1800.00	杭州北京（现货）
Bellancom-136909	￥3000.00	杭州北京（现货）
Bellancom-136909	￥8500.00	杭州北京（现货）
Bellancom-136909	￥13000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SR33805

产品介绍

SR33805 是一种有效的 Ca²⁺ 通道拮抗剂，在去极化和极化条件下的 EC₅₀ 值分别为 4.1 nM 和 33 nM。SR33805 阻止 L 型而不是 T 型 Ca²⁺ 通道。SR33805 可用于研究急性或慢性心脏衰竭。

生物活性

SR33805 is a potent Ca²⁺ channel antagonist, with EC₅₀s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca²⁺ channels. SR33805 can be used for the research of acute or chronic failing hearts.

体外研究

SR33805 (0.01-10 µM; 3 d) inhibits growth factor-induced proliferation of SMC (0.2050<0.46 µM) in a dose-dependent manner.
SR33805 (10 µM; 10 min) restores the myocardial infarction (MI)-altered cell shortening without affecting the Ca²⁺ transient amplitude.
SR33805 (10 µM) decreases the activity of recombinant PKA.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Smooth muscle cells (SMC)
Concentration:	0.01, 0.1, 1, 10 µM
Incubation Time:	3 days
Result:	Inhibited in a dose-dependent manner FCS-, bFGF and PDGF-induced proliferation of porcine SMC with IC₅₀s of 0.26±0.08, 0.46±0.1 and 0.20±0.04 µM, respectively.

体内研究
(In Vivo)

SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats.
SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (5 weeks) are subjected to coronary artery ligature
Dosage:	0.2, 2, 20 mg/kg
Administration:	A single i.p. injection
Result:	Increased significantly both end-systolic strain (ESS) and fractional shortening (FS) by about +38 and +26%, respectively at the dose of 20 mg/kg. Did not affect other contractile parameters.

体内研究

SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats.
SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (5 weeks) are subjected to coronary artery ligature
Dosage:	0.2, 2, 20 mg/kg
Administration:	A single i.p. injection
Result:	Increased significantly both end-systolic strain (ESS) and fractional shortening (FS) by about +38 and +26%, respectively at the dose of 20 mg/kg. Did not affect other contractile parameters.

体内研究

SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats.
SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (5 weeks) are subjected to coronary artery ligature
Dosage:	0.2, 2, 20 mg/kg
Administration:	A single i.p. injection
Result:	Increased significantly both end-systolic strain (ESS) and fractional shortening (FS) by about +38 and +26%, respectively at the dose of 20 mg/kg. Did not affect other contractile parameters.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (177.07 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7707 mL	8.8536 mL	17.7073 mL
5 mM	0.3541 mL	1.7707 mL	3.5415 mL
10 mM	0.1771 mL	0.8854 mL	1.7707 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (3.68 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.68 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.68 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.68 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。